Treatment of tachyarrhythmias

Annals of Emergency Medicine

Volumn 37, Issue 4 SUPPL., 2001, Pages

  Atkins, Dianne L ^a   Dorian, Paul ^b   Gonzalez, Edgar R ^c   Gorgels, Anton P M ^d   Kudenchuk, Peter J ^e   Lurie, Keith G ^f   Morley, Peter T ^g   Robertson, Colin ^h   Samson, Ricardo A ⁱ   Silka, Michael J ^j   Singh, Bramah N ^k  

^a UNIVERSITY OF IOWA   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Medical Center ^*

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRETYLIUM; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; FLECAINIDE; LIDOCAINE; PHENYTOIN; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL;

CLINICAL PRACTICE; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEMODYNAMICS; HUMAN; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA;

EID: 17744363258     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1067/mem.2001.114125     Document Type: Article

References (214)

1. Wide complex tachycardia: Misdiagnosis and outcome after emergent therapy
2. Wide QRS complex tachycardia: Reappraisal of a common clinical problem
3. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex
4. The differential diagnosis of a regular tachycardia with a wide QRS complex on the 12-lead ECG: Ventricular tachycardia, supraventricular tachycardia with aberrant intraventricular conduction, and supraventricular tachycardia with anterograde conduction over an accessory pathway
5. The differential diagnosis on the electrocardiogram between ventricular tachycardia and preexcited tachycardia
6. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex
7. Electrocardiographic criteria for ventricular tachycardia in wide complex left bundle branch morphology tachycardias
8. Misdiagnosing ventricular tachycardia in patients with underlying conduction disease and similar sinus and tachycardia morphologies
9. Ventricular tachycardia may masquerade as supraventricular tachycardia in patients with preexisting bundle-branch block
10. Evaluation of the specificity of morphological electrocardiographic criteria for the differential diagnosis of wide QRS complex tachycardia in patients with intraventricular conduction defects
11. Failure to agree on the electrocardiographic diagnosis of ventricular tachycardia
12. Diagnostic clues from the surface ECG to identify idiopathic (fascicular) ventricular tachycardia: Correlation with electrophysiologic findings
13. Esophageal electrocardiography: A new technology revises an old technique
14. Esophageal electrocardiography in acute cardiac care: Efficacy and diagnostic value of a new technique
15. Transesophageal electrocardiography using a temporary pacing balloon-tipped electrode in acute cardiac care
16. Transesophageal electrocardiography and adenosine in the diagnosis of wide complex tachycardia
17. Lidocaine in the prevention of primary ventricular fibrillation: A double-blind, randomized study of 212 consecutive patients
18. Effects of prophylactic lidocaine in suspected acute myocardial infarction: An overview of results from the randomized, controlled trials
19. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction
20. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction
21. Prophylactic lidocaine use in acute myocardial infarction: Incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators
22. Lack of effectiveness of lidocaine for sustained, wide QRS complex tachycardia
23. Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction
24. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia
25. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia
26. Adenosine in the diagnosis of broad complex tachycardia
27. Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia
28. Intravenous adenosine triphosphate during wide QRS complex tachycardia: Safety, therapeutic efficacy, and diagnostic utility
29. Effects of intravenous adenosine on antegrade refractoriness of accessory atrioventricular connections
30. Life-threatening alterations in heart rate after the use of adenosine in atrial flutter
31. Dissociation of termination and prevention of inducibility of sustained ventricular tachycardia with infusion of procainamide: Evidence for distinct mechanisms
32. Intermittent intravenous procainamide to treat ventricular arrhythmias: Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure
33. Propafenone versus procainamide for conversion of atrial fibrillation to sinus rhythm
34. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion
35. Facilitating influence of procainamide on conversion of atrial flutter by rapid atrial pacing
36. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing
37. Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment
38. Procainamide infusion and acute atrial fibrillation
39. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion
40. The Wolff-Parkinson-White syndrome: Pharmacologic effects of procainamide
41. Differential effect of intravenous procainamide on anterograde and retrograde accessory pathway refractoriness
42. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: Importance of atrial fibrillatory cycle length
43. Use of procainamide in patients with the Wolff-Parkinson-White syndrome to disclose a short refractory period of the accessory pathway
44. Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome
45. Electrophysiologic effects and mechanisms of termination of supraventricular tachycardia by intravenous amiodarone
46. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm
47. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study
48. A comparison of amiodarone and digoxin for treatment of supraventricular arrhythmias after cardiac surgery
49. Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias
50. Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias
51. Ectopic automatic atrial tachycardia in children: Clinical characteristics, management and follow-up
52. Intravenous amiodarone in the acute termination of supraventricular arrhythmias
53. Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: A placebo-controlled study
54. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias
55. Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias
56. The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery
57. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation: Amiodarone vs quinidine for conversion of atrial fibrillation
58. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation
59. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: A randomized, digoxin-controlled study
60. Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation
61. Management of atrial tachyarrhythmias in the critically ill: A comparison of intravenous procainamide and amiodarone
62. A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone and DC cardioversion
63. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction
64. Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response
65. Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients
66. Efficacy and safety of intravenous amiodarone for short-term treatment of paroxysmal supraventricular tachycardia in children
67. Electrical cardioversion after amiodarone administration
68. Amiodarone prophylactics for tachycardias after coronary artery surgery: A randomized, double blind, placebo controlled study
69. Hemodynamic responses to amiodarone in critically ill patients receiving catecholamine infusions
70. Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient
71. Effect of intravenous amiodarone on electrophysiologic variables and on the modes of termination of atrioventricular reciprocating tachycardia in Wolff-Parkinson-White syndrome
72. The effective treatment of multifocal atrial tachycardia with amiodarone
73. Clinical efficacy and safety of intravenous amiodarone in infants and children
74. Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia
75. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation
76. Use of intravenous amiodarone for emergency treatment of life threatening ventricular arrhythmias
77. Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia
78. Acute hemodynamic and antiischemic effects of intravenous amiodarone
79. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group
80. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group
81. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular arrhythmias. The Intravenous Amiodarone Multicenter Investigators Group
82. Hemodynamic effects and tolerabitity of intravenous amiodarone in patients with impaired left ventricular function
83. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation
84. Effect of loading dose of procainamide on left ventricular performance in man
85. The antiarrhythmic properties of lidocaine and procainamide
86. Atrial tachyarrhythmias after cardiac surgery: Results of disopyramide therapy
87. Mechanisms of regular, wide QRS tachycardia in infants and children
88. Quinidine syncope in children
89. The effects of adenosine on idiopathic ventricular tachycardia
90. Postinfarction ventricular arrhythmias in children
91. Intravenous amiodarone for life-threatening tachyarrhythmias in children and young adults
92. Pediatric use of intravenous amiodarone: Efficacy and safety in critically ill patients from a multicenter protocol
93. Effectiveness and safety of intravenous amiodarone in drug-resistant tachyarrhythmias of children
94. Bretylium tosylate as initial treatment for cardiopulmonary arrest: Randomized comparison with placebo
95. Comparison of bretylium tosylate and lidocaine in management of out of hospital ventricular fibrillation: A randomized clinical trial
96. A randomized comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system
97. Pharmacologic basis for the treatment of cardiac arrhythmias
98. Pharmacologic therapy
99. Pharmacology and electrophysiology of antiarrhythmic drugs
100. Cardiac pacing in the long QT syndrome: Review of available data and practical recommendations
101. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome
102. Long QT syndromes and torsade de pointes
103. Treatment of torsade de pointes with magnesium sulfate
104. Early intervention with a beta-blocking drug after acute myocardial infarction
105. The Goteborg metoprolol trial: Effects on mortality and morbidity in acute myocardial infarction
106. Selective depression of the ischemic and hypoxic myocardium by lidocaine
107. Beneficial effect of lidocaine on ventricular electrical stability and spontaneous ventricular fibrillation during experimental myocardial infarction
108. Effect of lidocaine on the ventricular fibrillation threshold in the dog during acute ischemia and premature ventricular contractions
109. Familial polymorphic ventricular arrhythmias: A quarter century of successful medical treatment based on serial exercise-pharmacologic testing
110. Lidocaine in out-of-hospital ventricular fibrillation: Does it improve survival?
111. Lidocaine in cardiac resuscitation from ventricular fibrillation
112. Electrophysiological properties of canine Purkinje cells in one-day-old myocardial infarction
113. Effects of lidocaine on hypoxic and ischemic cardiac cells
114. Antifibrillatory effects of high dose bretylium and a lidocaine-bretylium combination during cardiopulmonary resuscitation
115. Lidocaine in prehospital countershock refractory ventricular fibrillation
116. Intravenous amiodaron-applikation bei therapierefraktarem kammerflimmern
117. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation
118. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? The DTAC Study Group
119. Resuscitation from ventricular fibrillation: Drug therapy
120. The effect of lidocaine and bretylium on the defibrillation threshold during cardiac arrest and cardiopulmonary resuscitation
121. Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs
122. Elevation of antiarrhythmic drugs on defibrillation energy requirements in dogs: Sodium channel block and action potential prolongation
123. Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements
124. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: Experimental studies
125. Bretylium tosylate versus lidocaine in experimental cardiac arrest
126. Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: Experimental study
127. Efficacy of bretylium tosylate for ventricular tachycardia
128. Deleterious effects of bretylium on hemodynamic recovery from ventricular fibrillation
129. Association of drug therapy with survival in cardiac arrest: Limited role of advanced cardiac life support drugs
130. Magnesium therapy for torsades de pointes
131. Pilot study of intravenous magnesium in refractory cardiac arrest: Safety data and recommendations for future studies
132. Randomized trial of magnesium in in-hospital cardiac arrest
133. Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation
134. Effects of amiodarone and its active metabolite desethyl-amiodarone on ventricular defibrillation threshold
135. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements
136. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: A prospective, randomized study
137. A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome
138. Intravenous flecainide acetate for supraventricular tachycardias
139. Electrophysiologic effects of intravenous propafenone at rest, during isoproterenol infusion and during exercise in the Wolff-Parkinson-White syndrome
140. Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia
141. Intravenous propafenone for termination of reentrant supraventricular tachycardia: A placebo-controlled, randomized, double-blind, cross over study
142. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias
143. Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome
144. Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia
145. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study
146. Effects of intravenous sotalol in patients with atrioventricular accessory pathways
147. Hemodynamic effects of intravenous flecainide in acute noncomplicated myocardial infarction
148. Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia
149. Hemodynamic effects of intravenous and oral sotalol
150. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial
151. Supraventricular tachycardia mechanisms and their age distributions in pediatric patients
152. Comparison of treatment of supraventricular tachycardia by Valsalva maneuver and carotid sinus massage
153. Treatment of paroxysmal supraventricular tachycardia in the emergency department by clinical decision analysis
154. Vagal techniques for termination of paroxysmal supraventricular tachycardia
155. The ice bag: A new technique for interruption of supraventricular tachycardia
156. Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia
157. Side effects of verapamil in infants
158. Cardiovascular collapse after verapamil in supraventricular tachycardia
159. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia
160. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias
161. Treatment of atrial ectopic tachycardia in infants <6 months old
162. A randomized double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery
163. Emergency management of atrial fibrillation and flutter: Intravenous diltiazem versus intravenous digoxin
164. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter
165. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias
166. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure
167. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and flutter: The Diltiazem-atrial Fibrillation/Flutter Study Group
168. Usefulness of diltiazem in the acute management of supraventricular tachyarrhythmias in the elderly
169. Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter
170. Esmolol: Safety and efficacy in postoperative Cardiothoracic patients with supraventricular tachyarrhythmias
171. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter
172. Esmolol: A new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias
173. Safety and efficacy of esmolol (ASL-8052: An ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardia
174. Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias
175. Clinical experience with intravenous metoprolol in supraventricular tachyarrhythmias: A multicentre study
176. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter
177. Atrial fibrillation and flutter: Immediate control and conversion with intravenously administered verapamil
178. Double-blind crossover randomized trial of intravenously administered verapamil: Its use for atrial fibrillation and flutter following open-heart surgery
179. Role of intravenous verapamil in supraventricular tachyarrhythmias after open-heart surgery
180. Treatment of supraventricular arrhythmias with intravenous and oral verapamil
181. Verapamil in atrial fibrillation and atrial flutter
182. Supraventricular tachyarrhythmias and rate-related hypotension: Cardiovascular effects and efficacy of intravenous verapamil
183. Short-term control of supraventricular tachycardia with verapamil infusion and calcium pretreatment
184. Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram
185. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin compared to placebo
186. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: The effect of no treatment and high-dose amiodarone: A randomized, placebo-controlled study
187. Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation
188. Effects of verapamil on the Electrophysiologic properties of the accessory pathway in patients with Wolff-Parkinson-White syndrome
189. Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome Pacing
190. Digitalis in the pre-excitation syndrome
191. Antithrombotic therapy in atrial fibrillation
192. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: Final results of a prospective 4.5-year study
193. Transesophageal echocardiographic evaluation on left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation
194. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation
195. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation
196. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation: Ibutilide Repeat Dose Study Investigators
197. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study
198. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation
199. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: Electrophysiological determinants of enhanced conversion efficacy
200. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function
201. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment
202. Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide
203. Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias
204. Intravenous propafenone in paroxysmal atrial fibrillation: A randomized, placebo-controlled, double-blind, multicenter trial
205. Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: A placebo-controlled study
206. Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery
207. Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent onset atrial fibrillation
208. Efficacy of intravenous propafenone in acute atrial fibrillation complicating open-heart surgery
209. Restoration of sinus rhythm in atrial fibrillation of recent onset using intravenous propafenone
210. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset
211. Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass: Comparison with disopyramide and digoxin in a randomized trial
212. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group
213. Natural history of isolated atrial flutter in infancy
214. Evaluation of a staged treatment protocol for rapid automatic junctional tachycardia after operation for congenital heart disease